[1] Froguel P, Vaxillaire M, Sun F, et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus[J]. Nature,1992, 356(6365):162-164. [2] Byrne M M, Sturis J, Clement K, et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations[J].J Clin Invest,1994, 93(3):1120-1130. [3] Stride A, Vaxillaire M, Tuomi T, et a1. The genetic abnormality in the beta cell determines the response to an oral glucose load[J].Diabetologia,2002,45(3):427-435. [4] Ellard S, Bellanne-Chantelot C, Hattersley A T. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young[J]. Diabetologia,2008, 51(4):546-553. [5] Ma Y, Han X, Zhou X, et al. A new clinical screening strategy and prevalence estimation for glucokinase variant-induced diabetes in an adult Chinese population[J]. Genet Med,2019, 21(4):939-947. [6] Stoffel M, Froguel P, Takeda J, et al. Human glucokinase gene:isolation, characterization, and identification of two missense mutations linked to early-onset non-insulin-dependent (type 2) diabetes mellitus[J]. Proc Nat Acad Sci USA,1992, 89(16):7698-7702. [7] Ping Xiao Y, Hua Xu X, Lan Fang Y, et al. GCK mutations in Chinese MODY2 patients:a family pedigree report and review of Chinese literature[J]. J Pediatr Endocrinol Metab, 2016, 29(8):959-964. [8] 王志新,平凡,张茜,等.中国妊娠期血糖异常人群葡萄糖激酶基因突变初步筛查[J].中华糖尿病杂志,2014,6(6):397-401. [9] Liu L,Liu Y,Ge X, et al. Insights into pathogenesis of five novel GCK mutations identified in Chinese MODY patients[J]. Metabolism, 2018 Dec, 89:8-17. [10] Craig M E, Jefferies C, Dabelea D, et al. ISPAD clinical practice consensus guidelines 2014. Definition, epidemiology, and classification of diabetes in children and adolescents[J]. Pediatr Diabetes, 2014,15(S20):4-17. [11] Chakera A J, Spyer G, Vincent N, et al. The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy:the Atlantic Diabetes in Pregnancy cohort[J]. Diabetes Care,2014, 37(5):1230-1236. [12] Lachance C H, Baillargeon M. Should the clinical criteria for suspecting glucokinase mutation-related hyperglycemia (MODY-2) be revisited during pregnancy?[J]. Can J Diabetes,2018, 42(3):226-228. [13] Chakera A J, Steele A M, Gloyn A L, et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation[J]. Diabetes care,2015, 38(7):1383-1392. [14] Stride A, Shields B,Gill-Carey O, et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia[J]. Diabetologia, 2014,57(1):54-56. [15] Gloyn A L, van de Bunt M, Stratton I M, et al. Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia[J]. Diabetologia, 2009, 52(1):172-174. [16] Chakera A J, Steele A M, Gloyn A L, et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation[J]. Diabetes Care,2015, 38(7):1383-1392. [17] Wang Z, Ping F, Zhang Q, et al. Preliminary screening of mutations in the glucokinase gene of Chinese patients with gestational diabetes. J Diabetes Investig, 2018,9(1):199-203. |